CM Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

CM Management’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,000	Closed	-$11K	–	73
2023 Q2	$11K	Hold	6,000	–	–	0.01%	73
2023 Q1	$22K	Sell	6,000 -11,500	-66%	-$53.1K	0.03%	62
2022 Q4	$67K	Sell	17,500 -5,000	-22%	-$25.6K	0.08%	70
2022 Q3	$178K	Buy	22,500 +4,000	+22%	+$66.2K	0.2%	70
2022 Q2	$389K	Buy	18,500 +2,250	+14%	+$52.8K	0.41%	62
2022 Q1	$611K	Buy	16,250 +8,750	+117%	+$302K	0.51%	58
2021 Q4	$422K	Buy	7,500 +3,750	+100%	+$252K	0.32%	77
2021 Q3	$271K	Buy	+3,750	New	+$287K	0.2%	84

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management

Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Prelude Capital Management New York $1.3B AUM 62.01% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return